NUSINERSEN
nusinersen 12 mg/5 mL intrathecal injection, 5 mL vial
NUSINERSEN (12972R)
12972R
Manner of administration:Injection
Restriction
Indication: Spinal muscular atrophy (SMA)
Treatment phase: Initial treatment occurring after onasemnogene abeparvovec therapy in a patient with
one of: (i) Type 1 SMA, or, (ii) pre-symptomatic SMA
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 3 | DPMQ: $104,500.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Spinraza | |||||